<?xml version="1.0" encoding="UTF-8"?>
<p>Remdesivir, a nucleotide analog, inhibits the EBOV RNA-dependent RNA-polymerase. Preliminary findings in a total of 499 patients that received treatment with Remdesivir against the disease of EBOV showed a mortality rate of 33% in patients in the early infectious stages. The same authors noted a 75% mortality rate in 1900 infected subjects that were not treated during the epidemic [
 <xref rid="B61-medicina-56-00386" ref-type="bibr">61</xref>].
</p>
